My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

SpringWorks Therapeutics: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving ↗

December 05, 2023

SpringWorks Therapeutics Inc (NASDAQ: SWTX) shares are trading lower by 8.4% to $29.00 Tuesday morning after the company announced the pricing of a publ

Via Benzinga

Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 30, 2023

Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

November 29, 2023

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

August 24, 2023

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

July 20, 2023

Via Benzinga

La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday ↗

November 30, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday.

Via Benzinga

Topics Stocks

Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 28, 2023

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 28, 2023

Via Benzinga

The Latest Analyst Ratings for SpringWorks Therapeutics ↗

June 06, 2023

Via Benzinga

SpringWorks Therapeutics: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Analyst Expectations for SpringWorks Therapeutics's Future ↗

April 20, 2023

Via Benzinga

SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment ↗

November 28, 2023

The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors.

Via Investor's Business Daily

PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗

November 28, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday.

Via Benzinga

Topics Stocks

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 28, 2023

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...

Via Benzinga

FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas ↗

November 28, 2023

The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who

Via Benzinga

4 Analysts Have This to Say About SpringWorks Therapeutics ↗

December 01, 2022

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

November 04, 2022

Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings:

Via Benzinga

SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK ↗

September 07, 2022

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know ↗

November 20, 2023

Via Benzinga

What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? ↗

November 16, 2023

SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with...

Via Benzinga

SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update ↗

August 24, 2023

In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which...

Via Benzinga

Get In Now. 7 Stocks That Are Set to Soar. ↗

April 13, 2023

While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas.

Via InvestorPlace

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

SpringWorks Therapeutics: Q3 Earnings Insights ↗

November 03, 2022

SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

NIO, Lucid Group And Other Big Gainers From Monday ↗

September 13, 2022

U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday ↗

August 11, 2022

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.